past
decad
report
incid
human
metapneumoviru
hmpv
increas
owe
use
molecular
assay
diagnosi
respiratori
viral
infect
cancer
patient
season
infect
differ
sampl
strategi
across
institut
small
sampl
size
publish
studi
make
difficult
appreci
true
incid
impact
hmpv
infect
systemat
review
summar
publish
data
hmpv
infect
hematopoiet
cell
transplant
recipi
patient
hematolog
malign
focus
incid
hmpvassoci
lower
respiratori
tract
infect
lrti
mortal
prevent
manag
ribavirin
andor
intraven
immunoglobulin
although
incid
hmpv
infect
hmpvassoci
lrti
patient
popul
similar
respiratori
syncyti
viru
parainfluenza
viru
despit
lack
direct
antivir
therapi
mortal
rate
remain
low
unless
patient
develop
lrti
absenc
vaccin
prevent
hmpv
infect
control
measur
recommend
reduc
burden
cancer
patient
use
sensit
polymeras
chain
reaction
pcr
assay
led
increas
awar
identif
human
metapneumoviru
hmpv
common
caus
respiratori
viral
infect
hematopoiet
cell
transplant
hct
recipi
hematolog
malign
hm
patient
recent
discov
negativesens
rna
paramyxoviru
hmpv
genet
similar
respiratori
syncyti
viru
rsv
reportedli
infect
approxim
hct
recipi
progress
upper
respiratori
tract
infect
urti
lower
respiratori
tract
infect
lrti
occur
case
report
fatal
rate
hct
recipi
bronchoalveolar
lavag
posit
hmpv
present
clinic
indistinguish
respiratori
virus
growth
unreli
cultur
thu
viral
infect
best
diagnos
use
pcrbase
assay
direct
antigen
detect
drug
found
activ
viru
vitro
ribavirin
howev
dearth
knowledg
viru
case
report
meet
abstract
includ
due
limit
literatur
topic
also
search
clinic
trial
registri
us
nation
institut
health
wwwclinicaltrialsgov
identifi
regist
clinic
trial
hmpv
infect
definitionsinfect
episod
subsequ
outcom
determin
author
origin
articl
use
variou
definit
howev
summar
version
definit
use
current
review
hmpv
case
patient
posit
nasal
wash
nasopharyng
swab
bronchoalveolar
lavag
hmpv
viral
diagnost
test
includ
review
hmpvlrti
defin
onset
respiratori
symptom
new
chang
pulmonari
infiltr
seen
chest
xray
ct
scan
chest
andor
viru
isol
lower
respiratori
sampl
eg
endotrach
tube
aspir
sputum
bronchoalveolar
lavag
fluid
hmpvmortal
death
attribut
hmpv
persist
progress
infect
respiratori
failur
identifi
time
death
two
author
dp
pk
independ
screen
abstract
use
predefin
inclus
exclus
criteria
four
author
dp
pk
jma
fec
use
standard
code
rule
abstract
import
variabl
final
list
articl
independ
discrep
resolv
discuss
primari
variabl
interest
studi
incid
hmpv
infect
progress
hmpvurti
hmpvlrti
hmpvassoci
mortal
antivir
therapi
includ
ribavirin
aerosol
intraven
oral
alon
combin
intraven
immunoglobulin
ivig
effect
antivir
therapi
measur
compar
incid
rate
outcom
treat
untreat
patient
outcom
data
select
fulltext
articl
valid
rfc
studi
report
outcom
hm
patient
hct
recipi
data
abstract
split
two
part
captur
characterist
outcom
group
respect
agreement
two
independ
author
first
second
phase
fulltext
select
process
check
calcul
cohen
kappa
outcom
ie
lrti
death
descript
summar
percentag
compar
treat
untreat
patient
outcom
use
chisquar
fisher
exact
test
appropri
odd
ratio
or
calcul
confid
interv
ci
statist
analys
perform
use
stata
softwar
version
stata
corp
colleg
station
tx
usa
p
valu
consid
signific
abstract
retriev
hmpv
review
electron
search
manual
search
specif
hmpv
infect
defin
popul
henc
screen
review
studi
respiratori
virus
overlap
data
includ
studi
incomplet
inform
exclud
review
leav
fulltext
articl
abstract
hmpv
incid
case
report
data
outcom
diagnost
method
studi
studi
screen
flowchart
shown
figur
agreement
two
author
select
abstract
select
fulltext
measur
cohen
kappa
ci
respect
regard
substanti
excel
clinic
present
hmpv
infect
similar
respiratori
infect
rsv
piv
rang
mild
urti
lrti
progress
respiratori
failur
death
common
present
symptom
hmpv
fever
cough
nasal
congest
rhinorrhea
headach
sore
throat
dyspnea
along
prodrom
symptom
diagnos
hmpv
infect
particularli
depend
avail
rtpcr
viral
cultur
yield
extrem
low
result
delay
cytopath
effect
hmpv
mask
concurr
viral
infect
earlier
studi
use
direct
fluoresc
antigen
assay
cultur
report
almost
doubl
yield
better
sensit
test
rtpcr
recent
studi
found
rtpcr
detect
high
viral
load
bronchoalveolar
lavag
sampl
hct
recipi
hmpvlrti
median
copiesml
viral
rna
serum
sampl
patient
pneumonia
may
indic
sever
diseas
report
radiolog
find
hmpvlrti
includ
diffus
alveolar
interstiti
infiltr
bibasilar
treeinbud
nodular
ground
glass
opac
scatter
small
nodul
basal
shadow
extens
air
space
consolid
pleural
effus
incid
hmpv
infect
studi
shown
tabl
overal
hmpv
infect
identifi
patient
evalu
studi
examin
hm
patient
hct
recipi
combin
give
incid
report
rang
incid
hmpv
infect
hm
patient
differ
observ
hct
recipi
furthermor
hmpv
infect
rate
adult
patient
slightli
higher
observ
children
specif
risk
factor
hmpv
infect
report
studi
incid
hmpvlrti
hm
patient
hct
recipi
hmpv
infect
report
studi
display
tabl
twenti
seven
hmpvlrti
case
hmpv
infect
observ
give
incid
report
rang
hmpvlrti
stratifi
hmpvlrti
rate
hm
patient
avail
comparison
hct
recipi
possibl
risk
factor
hmpvlrti
studi
detail
henc
difficult
identifi
highrisk
patient
identifi
two
studi
examin
rel
largescal
singleinstitut
retrospect
data
hmpv
infect
cancer
patient
first
studi
examin
hct
recipi
hmpv
infect
found
signific
associ
steroid
use
within
week
prior
diagnosi
hr
low
lymphocyt
count
hr
earli
onset
hmpv
infect
hct
day
hct
hr
progress
lrti
adjust
hazard
ratio
p
valu
base
bivari
cox
regress
analysi
higher
hmpv
viral
load
nasal
wash
diagnosi
identifi
signific
predictor
lrti
progress
studi
second
studi
examin
cancer
patient
includ
patient
hm
solid
tumor
hct
recipi
hmpv
infect
overal
incid
lrti
independ
predictor
lrti
nosocomi
infect
hypoxia
present
report
studi
examin
patient
hmpv
infect
urti
lrti
patient
die
give
mortal
rate
rang
howev
mortal
rate
significantli
higher
patient
develop
hmpvlrti
ci
p
valu
find
remain
includ
five
studi
examin
patient
hmpvlrti
mortal
rate
death
hmpvlrti
case
similar
find
observ
overal
low
allcaus
mortal
hmpv
associ
mortal
day
followup
diagnosi
hmpv
infect
cancer
patient
differ
allcaus
mortal
rate
identifi
hm
patient
hct
recipi
statist
analysi
identifi
associ
hmpvmortal
rate
differ
type
underli
hm
possibl
due
insuffici
data
knowledg
risk
factor
hmpv
mortal
report
current
literatur
except
one
studi
report
corticosteroid
oxygen
requir
mechan
ventil
bone
marrow
cell
sourc
signific
risk
factor
respiratori
virusrel
mortal
specif
hmpvrelat
mortal
hct
recipi
characterist
manag
outcom
hmpv
infect
case
publish
case
report
display
supplement
tabl
patient
hmpv
infect
die
mortal
rate
follow
hmpvlrti
case
report
ribavirinbas
therapi
found
anecdot
effect
prevent
death
hmpv
immunocompromis
patient
howev
report
control
group
avail
data
case
report
use
antivir
therapi
outcom
patient
hmpv
infect
shown
supplement
tabl
four
patient
die
receiv
antivir
therapi
ar
ivig
ar
ivig
patient
surviv
patient
receiv
antivir
therapi
supplement
tabl
bivari
regress
analysi
use
data
tabl
show
ribavirin
therapi
signific
protect
effect
hmpvmortal
p
recent
studi
compar
mortal
rate
hct
recipi
hmpvlrti
treat
aerosol
ribavirin
intraven
polyclon
immunoglobulin
result
discourag
similar
mortal
rate
untreat
group
higher
hypoxemia
rate
addit
recent
case
seri
includ
children
cancer
leukemia
report
children
recov
ill
antiviraldirect
therapi
one
patient
prolong
respiratori
symptom
cohort
cancer
patient
hmpv
infect
patient
hmpvlrti
hct
hm
patient
hmpvuri
hct
treat
ar
one
patient
hm
lrti
die
day
systemat
review
attempt
summar
publish
data
hmpv
infect
hm
patient
hct
recipi
gener
meaning
conclus
incid
lrti
mortal
rate
manag
includ
antivir
therapi
prevent
measur
includ
vaccin
identifi
high
rate
hmpv
infect
hm
patient
hct
recipi
similar
observ
respiratori
virus
rsv
piv
incid
vari
wide
could
attribut
factor
patient
sampl
method
symptomat
versu
asymptomat
patient
age
transplant
underli
malign
type
season
studi
period
public
bia
diagnost
method
use
ie
rtpcr
vs
direct
fluoresc
antigen
assay
vs
cultur
rate
hmpv
infect
similar
hct
recipi
well
hm
patient
furthermor
high
morbid
rate
report
approxim
onethird
hmpv
infect
develop
lrti
despit
lack
direct
antivir
therapi
virusassoci
mortal
rate
remain
low
hmpv
infect
howev
patient
progress
lrti
stage
experienc
higher
mortal
rate
thu
import
prevent
lrti
patient
hmpv
infect
hmpvspecif
risk
factor
increas
mortal
identifi
recent
small
studi
compar
mortal
rate
rsvlrti
versu
hmpvlrti
hct
recipi
identifi
steroid
therapi
oxygen
requir
l
mechan
ventil
bone
marrow
cell
sourc
signific
risk
factor
overal
virusrel
mortal
howev
risk
factor
specif
rsv
hmpv
ribavirin
role
treat
hmpv
infect
hct
recipi
hm
patient
still
known
studi
report
success
treatment
hmpv
infect
ribavirin
without
intraven
polyclon
immunoglobulin
howev
data
limit
small
case
seri
case
report
ribavirin
hypothes
dual
mode
action
hmpv
direct
antivir
effect
hmpv
may
awaken
hyporespons
immun
system
prolong
viremia
observ
signific
protect
effect
ribavirin
prevent
hmpv
mortal
howev
sampl
size
small
adjust
confound
factor
possibl
supplement
tabl
thu
efficaci
ribavirin
prevent
lrti
mortal
infect
need
investig
absenc
investig
agent
infect
use
larg
retrospect
cohort
multiinstitut
prefer
random
clinic
trial
could
difficult
conduct
time
fashion
standard
ivig
administr
inhibit
hmpv
replic
vitro
potenti
benefit
hct
recipi
could
determin
current
publish
studi
concur
guidelin
fourth
european
confer
infect
leukemia
treatment
recommend
current
possibl
hmpv
infect
cancer
patient
advanc
report
gener
polyfunct
hmpv
specif
tcell
produc
multipl
cytokin
ifn
tnf
gmcsf
effector
molecul
granzym
b
upon
stimul
cognat
antigen
tcell
specif
f
n
p
antigen
hct
recipi
clear
hmpv
infect
thu
potenti
adopt
tcell
therapi
prevent
andor
treat
hmpv
infect
immunocompromis
patient
promis
search
clinic
trial
registri
publish
articl
identifi
report
new
investig
drug
develop
treatment
hmpv
infect
howev
monoclon
antibodi
moab
develop
prevent
treatment
hmpv
infect
moab
target
hmpv
fusion
protein
show
potenti
use
hmpv
prevent
promis
result
vitro
vivo
reduc
pulmonari
viral
titer
limit
bronchial
hyperact
prevent
sever
acut
manifest
furthermor
human
fab
human
moab
fragment
show
prophylact
therapeut
benefit
sever
hmpv
infect
vitro
mous
model
addit
phase
doubleblind
placebocontrol
studi
ongo
determin
safeti
immunogen
recombin
live
attenu
rhmpvpa
vaccin
deliv
intranas
healthi
adult
age
yr
hmpvseroposit
seroneg
children
although
live
attenu
viru
vaccin
may
promis
young
children
healthi
adult
use
immunocompromis
cancer
patient
may
recommend
final
specif
class
viral
subunit
vaccin
viruslik
particl
vlp
mimic
overal
viral
structur
antigen
conform
f
g
protein
induc
signific
crossprotect
immun
mice
vlp
offer
distinct
advantag
safe
specif
sustain
immun
respons
hmpv
infect
may
viabl
candid
trial
cancer
patient
absenc
effect
drug
vaccin
infect
control
measur
play
key
role
decreas
incid
hmpv
infect
prevent
nosocomi
outbreak
subsequ
morbid
mortal
immunocompromis
patient
howev
hmpv
infect
hct
recipi
may
subclin
make
difficult
halt
transmiss
viru
addit
prolong
viral
shed
day
immunocompromis
host
report
thu
includ
hmpv
test
routin
surveil
symptomat
hct
recipi
hm
patient
would
benefici
earli
identif
allow
patient
place
contact
isol
need
one
limit
systemat
review
exclus
nonenglish
languag
public
especi
develop
nation
addit
relianc
secondari
data
may
subject
interpret
error
tri
minim
two
differ
investig
dp
pk
valid
data
outcom
reconfirm
rfc
studi
retrospect
nonrandom
natur
henc
result
systemat
review
interpret
caution
attempt
decreas
public
bia
includ
almost
publish
studi
minim
exclus
criteria
anoth
limit
studi
lack
standard
definit
hmpvlrti
sinc
review
includ
heterogen
studi
popul
could
conduct
metaregress
analys
identifi
independ
effect
variou
host
risk
factor
progress
lrti
final
due
inconsist
report
role
coinfect
antibiot
usag
prevent
progress
hmpvlrti
could
systemat
evalu
summari
knowledg
first
comprehens
review
hmpv
infect
hm
patient
hct
recipi
attempt
determin
actual
incid
infect
subsequ
lrti
mortal
patient
popul
base
review
identifi
high
morbid
low
mortal
associ
hmpv
infect
unless
infect
progress
lrti
stage
studi
focus
hmpv
infect
cancer
patient
need
determin
risk
factor
associ
lrti
mortal
role
exist
antivir
drug
prevent
sever
diseas
outcom
refer
web
version
pubm
central
supplementari
materi
acut
lymphoblast
leukemia
tabl
incid
hmpv
infect
hmpvlrti
hmpv
mortal
hct
recipi
hm
patient
n
cancer
lett
author
manuscript
avail
pmc
august
